Pre-Emptive Treatment with Nilotinib after Second Allogeneic Transplantation in a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patient with High Risk of Relapse | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Pre-Emptive Treatment with Nilotinib after Second Allogeneic Transplantation in a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patient with High Risk of Relapse

Acta Haematol (2010) 123 (4): 242–247.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Post-transplant leukemia relapse in organs: biology. and behavior in 585 reports

Isabel Cunningham

Critical Reviews in Oncology/Hematology (2021) 157: 103170.

18FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

Isabel Cunningham
Brigett Kohno

American Journal of Hematology (2016) 91 (4): 379.

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

Avichai Shimoni
Yulia Volchek
Maya Koren‐Michowitz
Nira Varda‐Bloom
Raz Somech
Noga Shem‐Tov
Ronit Yerushalmi
Arnon Nagler

Cancer (2015) 121 (6): 863.

Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation

Daniel N. Egan
Lan Beppu
Jerald P. Radich

Biology of Blood and Marrow Transplantation (2015) 21 (1): 184.

Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity

I.H. Bartelink
E.M.L. van Reij
C.E. Gerhardt
E.M. van Maarseveen
A. de Wildt
B. Versluys
C.A. Lindemans
M.B. Bierings
Jaap Jan Boelens

Biology of Blood and Marrow Transplantation (2014) 20 (3): 345.

Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant

Carmen Fava
Giovanna Rege-Cambrin
Alessandro Busca
Enrico Gottardi
Filomena Daraio
Giuseppe Saglio

Clinical Lymphoma Myeloma and Leukemia (2013) 13: S272.

The clinical behavior of 124 leukemic ovarian tumors: clues for improving the poor prognosis

Isabel Cunningham

Leukemia & Lymphoma (2013) 54 (7): 1430.

Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation

Paul Farnsworth
David Ward
Vijay Reddy

Experimental Hematology & Oncology (2012) 1 (1)

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Michael S. Mathisen
Susan O’Brien
Deborah Thomas
Jorge Cortes
Hagop Kantarjian
Farhad Ravandi

Current Hematologic Malignancy Reports (2011) 6 (3): 187.

Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies

Aleksandra Petrovic
Gregory Hale

Expert Review of Clinical Immunology (2011) 7 (4): 515.

Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options

Kirk R Schultz
Tim Prestidge
Bruce Camitta

Expert Review of Hematology (2010) 3 (6): 731.